News
SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that ...
Pharmalittle: We’re watching Europe moving to reject Elevidys, a FDA panel on SSRI risks, and more
European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...
Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...
Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...
Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...
Explore more
A roundup of global health news reveals rising challenges, including Brazil's bird flu outbreak, vaccine policy changes by ...
1d
Zacks Investment Research on MSNHere's Why Novartis (NVS) is a Strong Value StockFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.
Indiana has a new name. With its growing field of precision medicine and life sciences, the state has secured the title of Radiopharmaceutical Capital of the World.
MIT professor, Dr. Leonard Guarente, conducts research into sirtuin genes and the power of a molecule called NAD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results